Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.
The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery. IPF is marked by declining lung function and eventual respiratory failure. It ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual meeting of the ...
Oncology program advancing with data expected in the fourth quarter 2025BEACON-IPF close out activities to be completed in ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...
Ingelheim, Germany/Ridgefield, Connecticut, U.S. “This milestone represents a new era in the treatment of IPF, a rare and debilitating chronic condition that worsens lung function. Nerandomilast has ...
A quantitative phase microscopy image of biomolecular condensates reconstituted from RNA and four distinct RNA-binding proteins. Pixel brightness is proportional to the local thickness of a condensate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback